GlobeNewsWire
17 Feb 2026, 18:19 UTC · 31w ago
Verdict
Headline takes no side. We score INO −1.00 across three claims — strongly bearish.
−1.00strongly bearish
More negative than 95% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
A class action lawsuit has been filed against Inovio Pharmaceuticals and its officers alleging federal securities law violations.
More negative than 91% of claims this week
Inovio's submission of the INO-3107 BLA to the FDA was delayed by approximately one year to mid-2025 due to manufacturing issues with the CELLECTRA device.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More negative than 87% of claims this week
The lawsuit claims Inovio lacked sufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review.
More negative than 79% of claims this week
Which stocks this story touches
More negative than 95% of ticker scores this week
The company is facing a class action lawsuit alleging materially false and misleading statements regarding its product pipelines and manufacturing capabilities.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
37m ago
−22.3%
Price agrees with the score
$1.25 vs $1.61 close before publication (Feb 13) · not market-adjusted
INO chart →
